Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59


Paracrine and cell autonomous signalling in pancreatic cancer progression and metastasis.

Thomas SK, Lee J, Beatty GL.

EBioMedicine. 2020 Mar;53:102662. doi: 10.1016/j.ebiom.2020.102662. Epub 2020 Mar 2. Review.


Inflammatory networks cultivate cancer cell metastasis to the liver.

Lee JW, Beatty GL.

Cell Cycle. 2020 Mar;19(6):642-651. doi: 10.1080/15384101.2020.1728013. Epub 2020 Feb 13.


Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle.

Wattenberg MM, Beatty GL.

Semin Cancer Biol. 2020 Jan 15. pii: S1044-579X(20)30003-1. doi: 10.1016/j.semcancer.2020.01.002. [Epub ahead of print] Review.


Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.

Wattenberg MM, Asch D, Yu S, O'Dwyer PJ, Domchek SM, Nathanson KL, Rosen MA, Beatty GL, Siegelman ES, Reiss KA.

Br J Cancer. 2020 Feb;122(3):333-339. doi: 10.1038/s41416-019-0582-7. Epub 2019 Dec 2.


Hepatocytes prepare the soil for liver metastasis.

Lee JW, Beatty GL.

Mol Cell Oncol. 2019 Jun 24;6(5):e1632686. doi: 10.1080/23723556.2019.1632686. eCollection 2019.


Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.

Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL.

Mol Ther. 2019 Nov 6;27(11):1919-1929. doi: 10.1016/j.ymthe.2019.07.015. Epub 2019 Jul 30.


Peripheral Blood T-Cell Fitness Is Diminished in Patients With Pancreatic Carcinoma but Can Be Improved With Homeostatic Cytokines.

Xu J, Sai H, Li Y, Jordan AC, McGettigan SE, Chen JH, Bedoya F, Fraietta JA, Gladney WL, Melenhorst JJ, Beatty GL.

Cell Mol Gastroenterol Hepatol. 2019;8(4):656-658.e6. doi: 10.1016/j.jcmgh.2019.07.008. Epub 2019 Aug 6. No abstract available.


Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.

Stone ML, Beatty GL.

Pharmacol Ther. 2019 Sep;201:202-213. doi: 10.1016/j.pharmthera.2019.05.012. Epub 2019 May 31. Review.


Hepatocytes direct the formation of a pro-metastatic niche in the liver.

Lee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, Delman D, Graham K, Gladney WL, Hua X, Black TA, Chien AL, Majmundar KS, Thompson JC, Yee SS, O'Hara MH, Aggarwal C, Xin D, Shaked A, Gao M, Liu D, Borad MJ, Ramanathan RK, Carpenter EL, Ji A, de Beer MC, de Beer FC, Webb NR, Beatty GL.

Nature. 2019 Mar;567(7747):249-252. doi: 10.1038/s41586-019-1004-y. Epub 2019 Mar 6.


Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't-eat-me' signal.

Liu M, O'Connor RS, Trefely S, Graham K, Snyder NW, Beatty GL.

Nat Immunol. 2019 Jan 21;20(3):265-275. doi: 10.1038/s41590-018-0292-y.


Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.

Balachandran VP, Beatty GL, Dougan SK.

Gastroenterology. 2019 May;156(7):2056-2072. doi: 10.1053/j.gastro.2018.12.038. Epub 2019 Jan 18. Review.


A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors.

Beatty GL, Shahda S, Beck T, Uppal N, Cohen SJ, Donehower R, Gabayan AE, Assad A, Switzky J, Zhen H, Von Hoff DD.

Oncologist. 2019 Jan;24(1):14-e10. doi: 10.1634/theoncologist.2017-0665. Epub 2018 Aug 16.


Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.

Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, Gladney WL, Levine BL, Melenhorst JJ, Plesa G, June CH.

Gastroenterology. 2018 Jul;155(1):29-32. doi: 10.1053/j.gastro.2018.03.029. Epub 2018 Mar 20.


CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients.

Karakasheva TA, Dominguez GA, Hashimoto A, Lin EW, Chiu C, Sasser K, Lee JW, Beatty GL, Gabrilovich DI, Rustgi AK.

JCI Insight. 2018 Mar 22;3(6). pii: 97022. doi: 10.1172/jci.insight.97022.


Lysosomes Support the Degradation, Signaling, and Mitochondrial Metabolism Necessary for Human Epidermal Differentiation.

Monteleon CL, Agnihotri T, Dahal A, Liu M, Rebecca VW, Beatty GL, Amaravadi RK, Ridky TW.

J Invest Dermatol. 2018 Sep;138(9):1945-1954. doi: 10.1016/j.jid.2018.02.035. Epub 2018 Mar 9.


Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance.

Long KB, Collier AI, Beatty GL.

Mol Immunol. 2019 Jun;110:3-12. doi: 10.1016/j.molimm.2017.12.003. Epub 2017 Dec 19. Review.


CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer.

Bengsch F, Knoblock DM, Liu A, McAllister F, Beatty GL.

Cancer Immunol Immunother. 2017 Dec;66(12):1609-1617. doi: 10.1007/s00262-017-2053-4. Epub 2017 Aug 30.


IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.

Long KB, Tooker G, Tooker E, Luque SL, Lee JW, Pan X, Beatty GL.

Mol Cancer Ther. 2017 Sep;16(9):1898-1908. doi: 10.1158/1535-7163.MCT-16-0899. Epub 2017 Jun 13.


Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance.

Beatty GL, Eghbali S, Kim R.

Am Soc Clin Oncol Educ Book. 2017;37:267-278. doi: 10.14694/EDBK_175232.


Functio Laesa: Cancer Inflammation and Therapeutic Resistance.

Liu M, Kalbasi A, Beatty GL.

J Oncol Pract. 2017 Mar;13(3):173-180. doi: 10.1200/JOP.2016.020347. Review. Erratum in: J Oncol Pract. 2017 Jul;13(7):466.


First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle PA, Newton RC, Schaub R, Maleski J, Leopold L, Gajewski TF.

Clin Cancer Res. 2017 Jul 1;23(13):3269-3276. doi: 10.1158/1078-0432.CCR-16-2272. Epub 2017 Jan 4.


Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.

Beatty GL, Li Y, Long KB.

Expert Rev Anticancer Ther. 2017 Feb;17(2):175-186. doi: 10.1080/14737140.2017.1270208. Epub 2016 Dec 14. Review.


Expanding Tumor Lymphocytic Infiltration as a Prognostic Tool to Patients with NSCLC Who Are Treated with Radiotherapy?

Kalbasi A, Beatty GL, Berman AT.

J Thorac Oncol. 2016 Nov;11(11):e141-e142. doi: 10.1016/j.jtho.2016.07.029. No abstract available.


Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.

Zhang Y, Velez-Delgado A, Mathew E, Li D, Mendez FM, Flannagan K, Rhim AD, Simeone DM, Beatty GL, Pasca di Magliano M.

Gut. 2017 Jan;66(1):124-136. doi: 10.1136/gutjnl-2016-312078. Epub 2016 Jul 8.


Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.

Beatty GL, O'Hara M.

Pharmacol Ther. 2016 Oct;166:30-9. doi: 10.1016/j.pharmthera.2016.06.010. Epub 2016 Jun 29. Review.


Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma.

Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, Ben-Josef E, Beatty GL.

Clin Cancer Res. 2017 Jan 1;23(1):137-148. doi: 10.1158/1078-0432.CCR-16-0870. Epub 2016 Jun 28.


Overcoming Therapeutic Resistance by Targeting Cancer Inflammation.

Beatty GL.

Am Soc Clin Oncol Educ Book. 2016;35:e168-73. doi: 10.14694/EDBK_158948. Review.


IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma.

Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL.

Cancer Discov. 2016 Apr;6(4):400-413. doi: 10.1158/2159-8290.CD-15-1032. Epub 2016 Feb 19.


Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.

Beatty GL, Winograd R, Evans RA, Long KB, Luque SL, Lee JW, Clendenin C, Gladney WL, Knoblock DM, Guirnalda PD, Vonderheide RH.

Gastroenterology. 2015 Jul;149(1):201-10. doi: 10.1053/j.gastro.2015.04.010. Epub 2015 Apr 14.


Immune escape mechanisms as a guide for cancer immunotherapy.

Beatty GL, Gladney WL.

Clin Cancer Res. 2015 Feb 15;21(4):687-92. doi: 10.1158/1078-0432.CCR-14-1860. Epub 2014 Dec 12. Review.


T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH.

Cancer Immunol Res. 2013 Jul;1(1):26-31. doi: 10.1158/2326-6066.CIR-13-0006. Epub 2013 Apr 7.


Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH.

Cancer Immunol Res. 2014 Feb;2(2):112-20. doi: 10.1158/2326-6066.CIR-13-0170. Erratum in: Cancer Immunol Res. 2015 Feb;3(2):217.


Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma.

Beatty GL.

Oncoimmunology. 2013 Dec 1;2(12):e26837. Epub 2013 Oct 22.


Harnessing the antitumor potential of macrophages for cancer immunotherapy.

Long KB, Beatty GL.

Oncoimmunology. 2013 Dec 1;2(12):e26860. Epub 2013 Nov 4. Review.


T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH.

Cancer Immunol Res. 2013 Jul;1:26-31.


A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.

Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer PJ.

Clin Cancer Res. 2013 Nov 15;19(22):6286-95. doi: 10.1158/1078-0432.CCR-13-1320. Epub 2013 Aug 27.


CD40 immunotherapy for pancreatic cancer.

Vonderheide RH, Bajor DL, Winograd R, Evans RA, Bayne LJ, Beatty GL.

Cancer Immunol Immunother. 2013 May;62(5):949-54. doi: 10.1007/s00262-013-1427-5. Epub 2013 Apr 16. Review.


Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH.

Cancer Cell. 2012 Jun 12;21(6):822-35. doi: 10.1016/j.ccr.2012.04.025.


EMT and dissemination precede pancreatic tumor formation.

Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ.

Cell. 2012 Jan 20;148(1-2):349-61. doi: 10.1016/j.cell.2011.11.025.


CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.

Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH.

Science. 2011 Mar 25;331(6024):1612-6. doi: 10.1126/science.1198443.


Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation.

Beatty GL, Smith JS, Reshef R, Patel KP, Colligon TA, Vance BA, Frey NV, Johnson FB, Porter DL, Vonderheide RH.

Clin Cancer Res. 2009 Aug 1;15(15):4944-53. doi: 10.1158/1078-0432.CCR-08-3332. Epub 2009 Jul 14.


Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers.

Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, Kaplan DE, Chang KM, Domchek SM, Kanetsky PA, Fecher LA, Flaherty KT, Schuchter LM, Vonderheide RH.

Clin Cancer Res. 2009 Jul 1;15(13):4277-87. doi: 10.1158/1078-0432.CCR-09-0537. Epub 2009 Jun 23.


Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer.

Clark CE, Beatty GL, Vonderheide RH.

Cancer Lett. 2009 Jun 28;279(1):1-7. doi: 10.1016/j.canlet.2008.09.037. Epub 2008 Nov 14. Review.


Telomerase as a universal tumor antigen for cancer vaccines.

Beatty GL, Vonderheide RH.

Expert Rev Vaccines. 2008 Sep;7(7):881-7. doi: 10.1586/14760584.7.7.881. Review.


Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.

Beatty GL, Giantonio BJ.

Expert Rev Anticancer Ther. 2008 May;8(5):683-8. doi: 10.1586/14737140.8.5.683. Review.


Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance.

Domchek SM, Recio A, Mick R, Clark CE, Carpenter EL, Fox KR, DeMichele A, Schuchter LM, Leibowitz MS, Wexler MH, Vance BA, Beatty GL, Veloso E, Feldman MD, Vonderheide RH.

Cancer Res. 2007 Nov 1;67(21):10546-55.


Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.

Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Kolstad A, Fox R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE, Bishop MR.

Biol Blood Marrow Transplant. 2006 Nov;12(11):1150-60.

Supplemental Content

Loading ...
Support Center